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Background: Symptoms induced by caloric or non‐caloric satiety test meals and gas‐
tric	myoelectrical	activity	(GMA)	have	not	been	studied	in	patients	with	diabetic	gas‐
troparesis	(DGP)	before	and	after	intense	glucose	management.
Aims: We determined the effects of continuous subcutaneous insulin infusion (CSII) 
with continuous glucose monitoring (CGM) on GI symptoms, volume consumed, and 
GMA	 induced	 by	 the	 caloric	meal	 satiety	 test	 (CMST)	 and	water	 load	 satiety	 test	
(WLST)	in	DGP.
Methods: Forty‐five	patients	with	DGP	underwent	CMST	and	WLST	at	baseline	and	
24 weeks after CSII with CGM. Subjects ingested the test meals until they were com‐
pletely full. Visual analog scales were used to quantify pre‐ and postmeal symptoms, 
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1  | INTRODUC TION
Early satiety, fullness, abdominal discomfort, bloating, and nausea 
and vomiting are symptoms associated with gastroparesis that usu‐
ally increase after ingestion of meals.1 The rate of gastric emptying 
of solid test meals, which is used to define gastroparesis, is poorly 
related to these postprandial symptoms.2,3 Thus, the origin of post‐
prandial	 symptoms	 in	 gastroparesis	 remains	 unclear.	 Provocative	
test meals have not been studied to assess immediate postprandial 
symptoms	and	gastric	myoelectrical	activity	(GMA)	in	patients	with	
diabetic gastroparesis.
On the other hand, test meals have been frequently used to 
study postprandial symptoms in patients with postprandial distress 
syndrome or dysmotility‐like functional dyspepsia. These patients 
ingested lower volumes of caloric meals or non‐caloric water loads 
compared with healthy control subjects and reported upper gastro‐
intestinal symptoms similar to those reported by patients with gast‐
roparesis.4‐7	Patients	with	functional	dyspepsia	(dysmotility	subtype)	
ingested smaller volumes of water and developed symptoms and a 
variety of gastric dysrhythmias compared with healthy subjects.7 In 
subjects with gastroparesis, lower volumes of water ingested were 
associated with increased early satiety, postprandial fullness, and 
severity of delayed emptying.8 Thus, disorders of gastric capacity 
(accommodation or hypersensitivity) and gastric dysrhythmias, as 
unmasked by caloric meal satiety tests (CMST) or water load satiety 
tests (WLST), represent potential pathophysiological mechanisms 
related to postprandial symptoms in patients with gastroparesis.
The effects of intensive insulin treatment on meal‐related symp‐
toms	and	GMA	have	not	been	studied	in	patients	with	diabetic	gas‐
troparesis. Thus, the aims of the current study were to determine 
the	effect	of	the	CMST	and	WLST	on	upper	GI	symptoms	and	GMA	
in well‐characterized patients with diabetic gastroparesis before 
and after intensive, open‐label, continuous subcutaneous insulin 









Conclusions and inferences: (a) Satiety test meals elicited symptoms of nausea, bloat‐
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myoelectrical activity, gastroparesis cardinal symptom index, patient assessment of upper GI 
symptoms
Key Points
• Satiety testing with caloric or water load acutely evoked 
symptoms and gastric myoelectrical abnormalities, but 
these measures did not improve after 24 weeks of insu‐
lin therapy.
• To study the effects of continuous subcutaneous insu‐
lin infusion with continuous glucose monitoring on GI 
symptoms, volume consumed, and gastric myoelectri‐
cal activity induced by the caloric meal satietytest and 
water load satiety test.
•	 Patients	with	diabetic	gastroparesis	underwent	satiety	
testing with measures of gastric myoelectrical activity 
before and after intensive insulin therapy for 24 weeks.
• Volumes of caloric meal and water load, symptoms in‐
duced by these two satiety meals, and gastric myoe‐
lectrical activity were not improved by intensive insulin 
therapy.
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infusion (CSII) therapy and continuous glucose monitoring (CGM) for 
24 weeks. The patients were enrolled in the Gastroparesis Clinical 
Research Consortium study protocol GLUMIT‐DG and had monthly 
clinic visits to assess glucose levels, adjust insulin doses, and review 
diets in order to assess safety of the intensive insulin treatment ap‐
proach.9 We hypothesized that the CMST and WLST would evoke 
upper gastrointestinal symptoms and gastric dysrhythmias in pa‐
tients with diabetic gastroparesis and that the ingested volumes, the 
meal‐induced	symptoms,	and	GMA	would	improve	if	better	glucose	




Forty‐five patients with diabetic gastroparesis who participated 
in the GLUMIT‐DG study were studied. The patients were re‐
cruited	from	seven	centers	of	the	GpCRC.	Patients	had	symptoms	
for	 ≥1	 year	with	GCSI	 scores	˃18.	 Subjects	 had	upper	 endoscopy	
within 1 year to exclude other reasons for symptoms. Gastroparesis 
was confirmed with gastric scintigraphy before registration with 
˃60%	meal	retention	at	2	hours	and/or	˃10%	at	4	hours.10 Type 1 
diabetes versus type 2 diabetes was determined by the site investi‐
gator based on patient history and review of records.
2.2 | Continuous subcutaneous insulin infusion and 
continuous glucose monitoring protocol
Patients	 were	 instructed	 in	 operating	 the	 CSII	 device	 (MiniMed	
Paradigm®Model 722 or Model 723, Medtronic) coupled with 
the	 MiniLink™	 REAL‐Time	 Transmitter	 CGM	 system	 (Medtronic).	
Subjects needed to show competency in (a) checking glucose levels 
with	CGM	plus	 finger	 stick	methods	≥	4×	daily,	 (b)	managing	CSII	
including adjusting insulin dosing as described below, and (c) elec‐
tronically transferring CGM data from their home computer to the 
GLUMIT‐DG	study	staff	every	2	weeks	(CareLink,	Medtronic).	After	
successful completion of the Run‐In, patients were formally enrolled 
in GLUMIT‐DG and permitted to progress to the 24‐week treatment 
and follow‐up phase.9
2.3 | Electrogastrography
After	 an	 overnight	 fast,	 the	 subjects	 had	 a	 finger	 stick	 glucose	
level	 to	 confirm	 glucose	 was	 <270	 gm/dL.	 If	 glucose	 was	 over	
270 mg/dL, then the glucose level was treated or the test was re‐
scheduled. Subjects were seated in a comfortable chair in a quiet 
area.	EKG‐type	electrodes	were	placed	in	standard	position	on	the	
upper abdominal surface after the skin was cleaned with alcohol 
wipes. Electrodes were connected to the electrogastrogram (EGG) 
recording	device	(3CPM	Company).	The	EGG	signal	was	digitized	
for computer analysis.7,11	Patients	had	a	15‐minute	baseline	EGG	
recording followed by one of the two satiety test protocols listed 
below.	Patients	returned	on	another	day	for	the	other	of	the	two	
EGG with satiety test protocols.
The	percentage	distribution	of	GMA	power	in	the	four	frequency	
ranges listed below was averaged for Time 0 (before meal ingestion) 
and for the 10‐minute periods after ingestion of the WLST or CMST 
for	group	analyses	at	baseline	and	24	weeks.	An	EGG	clinical	diagno‐
sis was also determined for the WL test for each subject by compar‐
ing values from historical subjects.7 The individual EGG diagnoses 
were as follows: normal (2.5‐3.5 cpm), tachygastria (3.5‐10 cpm), 
bradygastria (1‐2.5 cpm), mixed gastric dysrhythmia (a combina‐
tion of tachygastria and bradygastria), and duodenal‐respiration 
(10‐15	cpm).	These	diagnoses	were	based	on	the	GMA	response	to	
the	WL	as	determined	by	the	percentage	distribution	of	GMA	power	
in the four frequency ranges in response to WLST.7 EGG recordings 
from the clinical centers were reviewed and edited at one site (Wake 
Forest)	by	one	of	the	authors	(KK)	who	was	blinded	to	the	study	site	
and to baseline or Week 24 visit.
2.4 | Provocative liquid test meals protocols
2.4.1 | Water load satiety test
Subjects ingested water until they achieved the sensation of “com‐
pletely full” during a five‐minute time period.7 The volume of water 
ingested was recorded. The subjects indicated the intensity of 
fullness, hunger, abdominal discomfort, bloating, and nausea on a 
100	mL	visual	analog	scale	(VAS)	before	and	10,	20,	and	30	minutes	
after	the	water	was	ingested.	GMA	was	recorded	for	15	minutes	be‐
fore the WL was ingested and for 30 minutes afterward using elec‐
trogastrography methods.
2.4.2 | Caloric meal satiety test
Subjects ingested 150 mL of Ensure® every four minutes with 
no time limit until they were “completely full”.11 The volume of 
Ensure®	ingested	was	recorded.	The	subjects	used	a	100	mL	VAS	
to rate the symptoms noted above before and 10, 20, 30, and 
60	minutes	after	the	CMST.	GMA	was	recorded	for	15	minutes	for	




abdominal	 discomfort,	 and	 nausea)	 and	 percentage	 GMA	 in	 the	
four frequency ranges were stratified by CMST and WLST sati‐
ety test results. Changes in meal volume between baseline and 
24 weeks were assessed using the paired t test. For comparisons 
within	 the	WLST,	 symptoms	and	GMAs	used	one	presatiety	 test	
time and three postsatiety test times at 10, 20, and 30 minutes. For 
comparisons within the CMST, symptoms used one presatiety test 
time and four postsatiety test times at 10, 20, 30, and 60 minutes, 
whereas	GMAs	used	one	presatiety	test	time	and	six	postsatiety	
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test times at 10, 20, 30, 40, 50, and 60 minutes. Comparisons be‐
tween the WSTL and CMST used time tests that were common to 
both, namely the one presatiety test time and the three postsati‐
ety test times at 10, 20, and 30 minutes. Mean scores for symp‐
toms	and	GMAs	compared	the	baseline	vs	24‐week	visit	assessed	
at the presatiety and postsatiety test times. Changes in scores 
for	symptoms	and	GMAs	compared	presatiety	vs	postsatiety	test	
times separately at the baseline and 24‐week visits. Repeated 
measures were analyzed using linear regression with mixed ef‐
fects. P	values	≤	.05	were	considered	statistically	significant.	The	




The patients were 31 women and 14 men ages 18 to 70 years. 
Thirty‐one patients had type 1 diabetes and 14 had type 2 diabe‐







of	 45).	 Almost	 half	 of	 the	 patients	were	 taking	 prokinetic	 agents,	
and	70%	were	taking	a	proton	pump	inhibitor.	The	T2DM	patients	
were	significantly	older,	had	higher	BMI,	used	less	continuous	insulin	
pump therapy, used more antidiabetic medications other than insu‐
lin, and had ingested lower mean volumes during the satiety water 
load and liquid nutrient tests compared to T1DM patients. Other de‐
mographic and standard laboratory results were similar in the two 
groups as previously published.9






with	 lower	 nausea/vomiting	 (35%),	 fullness/early	 satiety	 (17%),	
and	bloating/distention	 (21%)	sub‐scores	 (P	≤	 .002).	Quality‐of‐life	
scores	 improved	29%	 (P	<	 .0001).	Satiety	 test	 tolerance	 increased	
14%	(P	=	.05).	HbA1c	decreased	more	in	patients	with	type	2	diabe‐
tes	(T2DM)	(2.0%	±	2.1%	vs	0.7%	±	1.1%,	P = .002) but symptoms 
improved	more	in	patients	with	type	1	diabetes	(T1DM)	(32%	vs	1%,	
P = .01). Six severe hypoglycemic events occurred on treatment ver‐
sus one during screening (0.3 vs 0.1/person‐year, P = .23).9
Of the 45 subjects in the current study, 43 and 44 subjects had 
EGGs	with	WLSTs	and	CMSTs,	respectively,	at	baseline.	At	24	weeks,	
37 and 39 subjects had EGGs with WLSTs and CMSTs, respectively. 
EGGs were not obtained or analyzed at 24 weeks in 11 patients be‐
cause (a) patients were not able to return for either the water load 
test or the satiety test, which were performed on separate days, or 
(b) movements of the arms, legs, or torso resulted in off scale deflec‐
tions of the EGG signal. EGG recordings with excessive movement 
artifact were not analyzed.
3.2 | Volumes ingested during the water load satiety 
test and caloric meal satiety test at baseline and 
24 weeks
The average volume of water ingested was 437 ± 216 mL at base‐
line and was 413 ± 238 at 24 weeks (P = .56; Figure 1). Volumes 
of water ingested in the five‐minute time limit ranged from 150 to 
TA B L E  1   Demographic and clinical characteristics of patients 
with diabetic gastroparesis










Time since diabetes diagnosis (y) 21 (11)
Hemoglobin	A1c	(%) 9.4 (1.4)





GCSI (Mean ± SD)
Nausea
Nausea component 3.5 (1.2)
Retching component 2.4 (1.6)
Vomiting component 2.3 (1.9)
Sub score 8.1 (4.2)
Fullness or early satiety
Stomach fullness component 3.9 (0.9)
Not able to finish component 3.3 (1.3)
Feeling excessively full component 3.9 (1.0)




Stomach visibly larger component 3.4 (1.4)
Subscore 7.1 (2.3)
Total GCSI 29.3 (7.1)
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1150	mL.	Historical	control	subjects	ingested	water	until	completely	
full using the same protocol, and the average volume ingested was 
648 ± 205 mL.14	Thus,	the	lower	limit	of	normal	was	set	at	˃238	mL	
water	ingested	in	five	minutes.	Using	this	cutoff,	24%	of	patients	had	
abnormal	WLSTs	at	baseline	and	27%	at	24	weeks.
The average volume ingested during the CMST was 427 ± 287 mL 
at baseline and was 480 ± 217 mL at 24 weeks (P = .44; Figure 1). 
Volumes ingested by our subjects ranged from 125 to 1422 mL to 
achieve the sense of “completely full.” The duration of ingestion 
ranged	 from	4	 to	 10	minutes.	Historical	 control	 subjects	 ingested	
800 to 1500 mL of a caloric load over unlimited time to achieve max‐
imum satiety using similar CMST protocols.4‐6 The CMST with a pro‐
tocol similar to the current study reported healthy subjects ingest 
1048 ± 421.5	Thus,	the	lower	range	of	normal	was	set	at	≥206	mL	
ingested.	Using	 this	 cutoff,	 15%	 and	19%	of	 the	 diabetic	 subjects	
ingested	<206	mL	at	baseline	and	at	24	weeks,	respectively.
3.3 | Symptoms and GMA in response to the water 
load and caloric meal satiety tests at baseline and 24‐
week visits
At	baseline	and	24	weeks	fullness	increased	and	hunger	decreased	
significantly and bloating and abdominal discomfort increased sig‐
nificantly	 after	 the	WLST	 (Ps	 <	 0.02;	 Figure	 2).	Nausea	 increased	
significantly after WLST at Week 24 (P	 <	 .01)	 but	 not	 at	 baseline	
(P = .08). There were no differences in the intensity of these symp‐
toms at 24 weeks compared with baseline.
Figure	3	shows	GMA	results	 in	the	bradygastria,	normogastria,	
tachygastria, and duodenal frequencies before (Time 0) and 10, 20, 
and 30 minutes after the subjects ingested water until they were 
completely full at baseline and 24‐week visits. The percentage of 
normal	3	cpm	GMA	and	 tachygastria	 increased	after	 the	WLST	at	
each visit but changes were not statistically significant. There were 
no	changes	in	the	average	percentage	distribution	of	GMA	in	these	
four frequency ranges at Week 24 compared with baseline values.
Figure 4 shows fullness, hunger, bloating, abdominal discomfort, 
and nausea before and after the CMST test. Compared with premeal, 
fullness increased and hunger decreased significantly and bloating, 
abdominal discomfort, and nausea increased significantly after the 
CMST	(Ps	<	0.01).	These	latter	three	symptoms	remained	significantly	
elevated for 60 minutes after the meal. There were no significant 
differences in the intensity of symptoms elicited by the CMST after 
24 weeks of CSII therapy compared with the baseline visit.
Figure	5	shows	GMA	 in	 the	bradygastria,	normogastria,	 tachy‐
gastria, and duodenal frequencies before and after the CMST. The 
percentage	distribution	of	GMA	decreased	significantly	in	the	brady‐
gastria range and increased significantly in the normal 3 cpm range at 
both	visits.	The	percentage	distribution	of	GMA	in	the	tachygastria	
range increased significantly (P = .002) at 24 weeks only. There were 
no	significant	differences	in	the	GMA	response	to	the	CMST	when	
the Week 24 visit was compared with baseline.
3.4 | Comparison of symptoms and GMA after 
water load and caloric meal satiety tests
At	baseline,	nausea	intensity	was	increased	similarly	after	ingestion	
of the CMST and WLST (P = .75). CMST evoked more fullness, less 
hunger, and more bloating and abdominal discomfort compared with 
the	WL	 test	 (Ps	 <	 0.01).	 After	 the	 CMST,	 bradygastria	 decreased	
and tachygastria increased significantly more compared with WLST 
(Ps	<	0.03).	The	normal	3	cpm	GMA	responses	to	WLST	and	CMST	
were similar (P = .41).
At	Week	24,	fullness,	bloating,	abdominal	discomfort,	and	nau‐
sea were significantly greater after CMST and hunger significantly 
less	compared	with	WLST	(Ps	<	0.01).	Bradygastria	was	decreased	
and tachygastria increased after CMST compared with WLST at 
F I G U R E  1   Volumes ingested by 
subjects	during	the	(A)	water	load	satiety	
test	(WLST)	and	(B)	caloric	meal	satiety	
test (CMST) test meals until they were 
completely full. The X axis shows baseline 
and Week 24 visits and the Y axis shows 
the volume in milliliters (mL) ingested 
at baseline and 24 wk after insulin 
pump therapy and continuous glucose 
monitoring. The volume of water ingested 
at baseline was 437 mL and 413 mL at 
24 wk (P = .86). The average volume of 
caloric test meal ingested at baseline was 





















P(24−week change in amount ingested) = .564
Water load satiety test





















P(24−week change in amount ingested) = .445
Caloric meal satiety test
Baseline visit wk 24 visit
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Week	24	(Ps	<	0.001).	Normal	3	cpm	GMA	responses	were	similar	
after WLST and CMST (P = .29).
3.5 | Clinical EGG diagnoses after water load satiety 
test at baseline and 24 weeks
Thirty‐one of the 45 patients had the EGG and WLST at baseline 
and Week 24 (Tables 2 and 3). The overall clinical EGG diagnoses 
were	 as	 follows:	At	 baseline	 the	EGG	was	normal	 in	 14	 subjects	
(45%)	and	abnormal	in	17	subjects	(six	had	tachygastria,	four	had	
bradygastria, three had mixed dysrhythmias, four had duodenal‐
respiration	 pattern).	 At	 24	weeks,	 10	 subjects	 (32%)	 had	 normal	
3	cpm	GMA	and	20	(68%)	had	dysrhythmias	(10	had	tachygastria,	
three had bradygastria, six had mixed dysrhythmias, one had the 
duodenal‐respiration pattern). The agreement in EGG diagnoses 
between	baseline	 and	24‐week	visits	was	55%.	Five	of	 these	31	
subjects	 (16%)	 had	 normal	 3	 cpm	 GMA	 at	 both	 baseline	 and	 at	
24	weeks.	Figure	6	shows	an	example	of	normal	3	cpm	GMA	be‐
fore and after the WLST and consistent 3 cpm peaks in the running 
spectral	analysis	of	the	GMA	in	a	patient	with	diabetic	gastropa‐
resis. Figure 7 shows gastric dysrhythmias before and after the 
WLST and peaks in the tachygastria range in the running spectral 
analysis in another patient.
4  | DISCUSSION
Symptoms and physiological measures immediately after meals 
have been infrequently studied in patient with diabetic gastropa‐
resis. On the other hand, satiety tests with barostat recordings 
have been studied frequently in patients with functional dyspepsia 
F I G U R E  2  Fullness	(A),	hunger	(B),	bloating	(C),	abdominal	discomfort	(D),	and	nausea	(E)	scores	are	shown	before	and	after	the	water	
load satiety test (WLST) test at baseline and at 24 wk. The X axis shows time in minutes. Time 0 indicates the 10 min before the test meal 
and 10, 20, and 30 min indicate time after ingestion. The Y	axis	shows	the	symptom	intensity	on	the	visual	analog	scale	(VAS)	in	millimeters	
(mm). Fullness increased significantly after the WLST and hunger decreased significantly at baseline and Week 24 visits. Symptoms of 
bloating and abdominal discomfort and nausea all increased significantly at the baseline visit, and bloating and abdominal discomfort 
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Nausea
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who ingest low volumes of the meals in association with decreased 
accommodation and/or gastric hypersensitivity.4‐6 In the current 
study,	 almost	 30%	 of	 our	 diabetic	 subjects	 ingested	 <236	 mL,	
which	is	<2	SD	below	the	mean	in	healthy	controls.5,14	Karamanolis	
et al found symptoms evoked with a 200 mL test meal correlated 
better with gastroparesis symptoms than the rate of gastric emp‐
tying or gastric accommodation in patients with idiopathic gas‐
troparesis.2 Gastroparesis patients who consumed small volumes 
(<250	mL)	during	the	WLST	had	increased	GCSI	scores,	especially	
nausea, and more severe delays in gastric emptying compared 
with	patients	who	consumed	normal	volumes	(˃557	mL).8 Nausea, 
bloating, and abdominal discomfort were reported within min‐
utes	after	the	caloric	meal	or	water	 load	were	 ingested.	Possible	
mechanisms include sensitivity to gastric distention, abnormalities 
in	 gastric	 accommodation,	 or	 both.	However,	 these	 possible	 ab‐
normalities were not investigated in this study.
The	 normal	 3	 cpm	GMA	 is	 associated	with	 normal	 numbers	
of gastric ICCs, the pacemaker cells that generate 3 cpm slow 
waves and coordinate gastric peristalsis during normal gastric 
emptying.15,16 Studies have suggested that the majority of dia‐
betic patients with gastroparesis have severe depletion of ICCs 
in the corpus and antrum (0‐3 ICCs/hpf) and gastric dysrhythmias 
ranging from tachygastria to bradygastria.15,16 Distention of the 
antrum with a balloon was associated with more upper GI symp‐
toms and more gastric dysrhythmias compared with distention of 
the fundus in healthy subjects.17 In our study, gastric dysrhyth‐
mias were evoked after ingestion of volumes of water in most pa‐
tients and included tachygastria, bradygastria, and mixed gastric 
F I G U R E  3  Gastric	myoelectrical	activity	(GMA)	before	and	after	the	water	load	satiety	test	at	baseline	and	at	24	wk.	Bradygastria	
(1.0‐2.5	cpm)	(A),	normogastria	(2.5‐3.5	cpm)	(B),	tachygastria	(3.5‐10	cpm)	(C),	and	duodenal‐respiration	(10‐15	cpm)	(D)	frequency	ranges	
are shown. The X axis indicates time in minutes with Time 0 indicating the 10 min before the test meal and the 10, 20, and 30‐minute 
periods after ingestion. The Y	axis	indicates	the	percent	distribution	of	GMA	power	in	the	four	frequency	ranges.	Normogastria	and	
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dysrhythmias.	 Symptoms	 and	 changes	 in	 3	 cpm	GMA	 increased	
after the CMST to a greater extent than with the WLST. Thus, 
distention of the antrum by liquid test meals in our patients with 
diabetic	gastroparesis	was	associated	with	changes	 in	GMA	and	
acute postprandial symptoms. Gastric dysrhythmias are also elic‐
ited when glucose levels are over 220 mg/dL in normal subjects18 




Sixteen percent of our patients with diabetic gastroparesis had 
normal	3	 cpm	GMA	 in	 response	 to	WLST	at	 both	baseline	 and	 at	
Week 24. In contrast to gastric dysrhythmias, the presence of normal 
3	cpm	GMA	suggests	normal	function	of	the	gastric	ICCs,	the	pace‐
maker cells of the stomach.15,16	Approximately,	20%	of	patients	with	
diabetic gastroparesis had normal numbers of ICCs by immunohisto‐
chemical stains from full‐thickness biopsies of the stomach corpus, 
although electron microscopy showed poor ICC‐nerve and ICC‐
smooth muscle contacts in these patients.20 Gastroparesis patients 
with	normal	3	cpm	GMA	may	have	a	fixed	or	functional	obstructive	
gastroparesis subtype21,22 secondary to pyloric dysfunction which 
may contribute to symptoms and the delay in gastric emptying.
We	 hypothesized	 that	 improvement	 in	 HbA1c	 after	 intense	
insulin therapy would improve symptoms elicited by the satiety 
tests	 and	GMA.	However,	 after	 24	weeks	 of	 CSII	 with	 CGM,	 the	
symptoms evoked by the caloric and non‐caloric satiety test meals 
were similar to baseline. Our previous study showed that intensive 
treatment	with	CSII	with	CGM	was	associated	with	a	23%	improve‐
ment	in	GCSI	and	a	1.1%	decrease	in	HbA1c	(from	9.4%	±	1.4%	to	
8.3%	 ±	 1.3%),	 supporting	 the	 importance	 of	 efforts	 to	 improve	
F I G U R E  4  Fullness	(A),	hunger	(B),	bloating	(C),	abdominal	discomfort	(D),	and	nausea	(E)	scores	are	shown	before	and	after	the	caloric	
meal satiety test (CMST) at baseline and 24 wk. The X axis shows time in minutes. Time 0 indicates the 10 min before the test meal and 10, 
20, 30, and 60 min indicates time after ingestion. The Y	axis	shows	the	symptom	intensity	on	the	visual	analog	scale	(VAS)	in	millimeters	
(mm). Fullness increased significantly after the CMST and hunger decreased significantly, and symptoms of bloating, abdominal discomfort, 
and nausea all increased significantly at baseline and the Week 24 visits. Compared with baseline visits, there were no significant changes in 
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glycemic control.9	However,	gastroparesis	symptoms	reported	using	
GCSI reflect a two‐week recall of symptoms and thus reflect an av‐
erage of symptoms related to daily meals and activities over time.9 In 
the current study, subjects ingested the liquid test meals until they 
were completely full, an acute challenge of gastric neuromuscular 
function that also allowed collection of meal‐induced symptoms in 
real	time	with	concomitant	GMA	recordings.	Under	these	test	meal	
conditions, the intense insulin therapy with CGM did not affect 
symptoms or physiological measures during the WLST or CMST.
F I G U R E  5  Gastric	myoelectrical	activity	(GMA)	before	and	after	the	caloric	meal	satiety	test	(CMST)	are	shown	at	baseline	and	at	
24	wk.	Bradygastria	(1.0‐2.5	cpm)	(A),	normogastria	(2.5‐3.5	cpm)	(B),	tachygastria	(3.5‐10	cpm)	(C),	and	duodenal‐respiration	(10‐15	cpm)	
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TA B L E  2   Electrogastrogram (EGG) diagnoses in response to 
water load satiety test in patients with diabetic gastroparesis at 
baseline and after 24 weeks of insulin therapy with continuous 
glucose monitoring
 Baseline Week 24
Normal 14 (45) 10 (32)
Tachygastria 6 (19) 11 (36)
Bradygastria 4 (13) 3 (10)
Mixed dysrhythmias 3 (10) 6 (19)
Duodenal‐respiration 4 (13) 1 (3)





Normal 5 9 14
Abnormal 5 12 17
Total 10 21 31
a55%	with	Kappa	value	0.06.	
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There are several potential reasons for the lack of improvement 
in symptoms and physiological measures in response to the satiety 
meal	tests:	(a)	HbA1c	decreased	1.1%	from	9.4%	to	8.3%	during	the	
6‐month treatment period, but hypo‐ and hyperglycemia events 
still	occurred	over	40%	of	 the	time	as	 recorded	with	CGM.9 Thus, 
the	overall	glycemic	control	remained	abnormal	at	8.3%.	The	1.1%	
improvement	 in	HbA1c	may	not	have	been	sufficient	 to	positively	
affect gastric neuromuscular function and symptoms in these pa‐
tients	 with	 diabetic	 GP;	 (b)	 our	 patients	 had	 known	 diabetes	 for	
an average of 21 years. The duration of treatment with CSII with 
F I G U R E  6  GMA	rhythm	strips	from	
the electrogastrogram recording from 
a subject with diabetic gastroparesis 
are	shown	in	A.	GMA	rhythm	strips	
from baseline (before WLST) and from 
10, 20, and 30 min after the WLST 
(labeled poststimulation period 1, 2, 
and 3, respectively). The X axis shows 
time in minutes and the Y axis shows 
microvolts. Note the 3 cycle per minute 
(cpm)	waves	in	GMA	at	baseline	(before	
water load) and in the rhythm strips 
from poststimulation period 1, 2, and 3 
which are from the 10, 20, and 30‐min 
periods after the WLST. Running spectral 
analysis	presented	in	B	are	from	the	GMA	
recordings	shown	in	6A.	The	X axis shows 
frequency from 1‐15 cpm. The Y axis 
shows time with each line representing 
4	min	of	GMA	with	75%	overlap.	The	
Z axis shows peaks that reflect the 
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CGM was 6 months, but a longer treatment and better control of 
glucose may be required to improve poor gastric accommodation, 
gastric dysrhythmias, and symptoms evoked by the satiety tests 
in	 these	patients.	 Improvement	 in	HbA1c	was	not	associated	with	
improved symptoms or rates of gastric emptying in other stud‐
ies23,24; (c) factors other than glycemic control may be important 
in	 meal‐induced	 symptoms	 and	 GMA	 abnormalities	 in	 diabetic	
gastroparesis.	Hyperglycemia	alone	was	not	enough	 to	cause	gas‐
troparesis in diabetic mice. In addition to hyperglycemia, a switch 
from M2 macrophages to M1 macrophages in the circular muscle 
layer and in the myenteric plexus of the stomach was required to 
develop gastroparesis.20	In	humans	with	DGP,	the	switch	from	M2	to	
F I G U R E  7  GMA	rhythm	strips	from	
an electrogastrogram (EGG) recording 
from a subject with diabetic gastroparesis 
are	shown	in	A.	GMA	rhythm	strips	from	
baseline (before WLST) and from 10, 
20, and 30 min after the WLST (labeled 
poststimulation period 1, 2, and 3, 
respectively). The X axis shows time in 
minutes and the Y axis shows microvolts. 
Note the lack of 3 cycle per minute (cpm) 
GMA	at	baseline	and	irregular	GMA	
after the WLST in the post stimulation 
time periods. Running spectral analysis 
presented	in	B	are	from	the	GMA	
recordings before and after the WLST 
shown	in	7A.	The	X axis shows frequency 
from 1‐15 cpm. The Y axis shows time 
with each line representing 4 min of 
GMA	with	75%	overlap.	The	Z axis shows 
peaks that reflect frequencies according 
to	amplitude	or	power	of	the	GMA	in	the	
EGG signal. The two flat lines indicate the 
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M1 macrophages in the gastric antrum is associated with decreased 
numbers of ICCs and gastric dysrhythmias.25 Thus, factors like mac‐
rophage switching and decreased ICC numbers, in addition to hyper‐
glycemia,	may	be	associated	with	the	GMA	dysfunctions	in	diabetic	
GP;	 and	 (d)	 sixteen	percent	of	 the	GP	 subjects	had	normal	3	 cpm	
GMA.	 In	 these	patients,	 pyloric	dysfunction	 is	 a	 key	 factor	 in	GP;	
and, pyloric therapies such as balloon dilation or injection of botuli‐
num	toxin	A	improve	symptoms.22 Therefore, diabetic patients with 
3	cpm	GMA	in	our	cohort	may	not	respond	to	insulin	and	may	have	
confounded the CSII with CGM therapy results.
The strengths of this study are that it is (a) a multicenter study 
of well‐characterized patients with diabetic gastroparesis with 
poorly controlled glycemia managed with CSII and CGM and (b) 
standard questionnaires, CSII with CGM treatment, and non‐caloric 
and	caloric	test	meals	with	standard	tests	of	GMA	were	obtained.	
Weaknesses of the study include: (a) lack of a disease control group 
in regards to insulin therapy, dietary counseling, and concomitant 
medications during the 24 weeks of intensive CSII with CGM treat‐
ment,	(b)	lack	of	a	healthy	control	group	for	symptoms	and	GMA	in	
response to the CMST, (c) unknown numbers of subjects with glu‐
cose levels between 220 mg/dL and 270 mg/dL during the CMST 
and WLST, and (d) analyses of combined type 1 and type 2 diabetes 
mellitus subjects because of the small number of subjects in each 
group limits generalization of results for either group.
In summary, liquid caloric and non‐caloric test meals immediately 
evoked significant increases in symptoms associated with gastropa‐
resis.	 Almost	 30%	 of	 patients	 ingested	 abnormally	 low	 volumes,	
suggesting poor gastric accommodation in a subset of patients with 
diabetic	gastroparesis.	Symptoms	and	3	cpm	GMA	 increased	after	
the CMST but not the WLST, indicating caloric meals are more po‐
tent	stimulants	of	symptoms	and	3	cpm	GMA.	More	aggressive	or	
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